Shares of Sarepta are down $1.49, or 1%, to $125.38 after resuming trading following the company’s announcement that the FDA granted accelerated approval of Elevidys gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy, or DMD, with a confirmed mutation in the DMD gene.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SRPT:
- 3 Best Stocks to Buy Now, 6/23/2023, According to Top Analysts
- Sarepta halted, pending news, ahead of FDA decision on SRP-9001
- Sarepta trading halted, news pending
- Before the Move: Watch Sarepta ahead of FDA decision on DMD gene therapy
- Regenxbio files second patent infringement suit against Sarepta